Prenetics Global (NASDAQ:PRE) Posts Quarterly Earnings Results

Key Points

• Prenetics Global reported a quarterly loss of ($0.82) EPS, with a negative net margin of 115.91% and a negative return on equity of 28.07%.
• The company's stock price increased to $10.03, significantly above its 52-week low of $3.09 and close to its high of $11.99.
• Prenetics received a rating upgrade to "hold" from Wall Street Zen, with an average analyst rating of "Buy" and a consensus target price of $9.00.

Prenetics Global (NASDAQ:PRE - Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.82) EPS for the quarter, Zacks reports. Prenetics Global had a negative net margin of 115.91% and a negative return on equity of 28.07%. Prenetics Global updated its FY 2025 guidance to EPS.

Prenetics Global Price Performance

PRE traded up $1.17 on Friday, reaching $10.03. 129,626 shares of the company traded hands, compared to its average volume of 35,012. The stock's 50 day moving average price is $7.99 and its 200-day moving average price is $6.67. Prenetics Global has a 52-week low of $3.09 and a 52-week high of $11.99. The company has a market cap of $130.12 million, a price-to-earnings ratio of -2.51 and a beta of 0.15.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Prenetics Global to a "hold" rating in a research note on Saturday, July 5th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Prenetics Global presently has an average rating of "Buy" and a consensus target price of $9.00.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.